Immunoassay and Mass Spectrometry Methods for Tau Protein Quantification in the Cerebrospinal Fluid

[1]  S. Lehmann,et al.  Antibody-free quantification of seven tau peptides in human CSF using targeted mass spectrometry , 2015, Front. Neurosci..

[2]  I. Grundke‐Iqbal,et al.  Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. , 2012, Journal of Alzheimer's disease : JAD.

[3]  J. Molinuevo,et al.  Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. , 2012, Biomarkers in medicine.

[4]  H. Vanderstichele,et al.  Cerebrospinal fluid collection tubes: a critical issue for Alzheimer disease diagnosis. , 2012, Clinical chemistry.

[5]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[6]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[7]  Hilkka Soininen,et al.  Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers , 2005, Annals of neurology.

[8]  K. Blennow,et al.  Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization , 2000, Neuroscience Letters.

[9]  M. Kirschner,et al.  Tau protein function in living cells , 1986, The Journal of cell biology.

[10]  F. Pasquier,et al.  Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study. , 2013, Journal of Alzheimer's disease : JAD.